Gufic Biosciences Ltd submits Q2 and H1 FY27 investor presentation, reporting three observations from the Indore US FDA pre-approval inspection.
- The three inspection observations are being addressed; the EU compliance report has been submitted and certification is awaited.
- Q2 FY27 registrations and first orders were secured in Saudi Arabia and Chile.
- Distribution expanded across five European countries through Gufic Ireland.
- The presentation covers unaudited results for the quarter and half year ended September 30, 2026; financial figures were not provided in the source material.
